African Development Bank Group invests USD 15 million in Biologicals and Vaccines Institute’s (Biovac) operations in South Africa

Lead party: The African Development Bank Group (AfDB) (lead investor/buyer)Coverage: Meridian Capital (investment and transaction tracker; data from Partner Researchers, editorially reviewed). Target: The Biologicals and Vaccines Institute of Southern Africa Proprietary Limited (private company) · Sector: Healthcare, Pharmaceuticals, Biotechnology · Countries of operation: Mozambique, Lesotho, Angola, Namibia, South Africa, Botswana, Eswatini Transaction type: Debt…


Lead party: The African Development Bank Group (AfDB) (lead investor/buyer)

Coverage: Meridian Capital (investment and transaction tracker; data from Partner Researchers, editorially reviewed).

Target: The Biologicals and Vaccines Institute of Southern Africa Proprietary Limited (private company) · Sector: Healthcare, Pharmaceuticals, Biotechnology · Countries of operation: Mozambique, Lesotho, Angola, Namibia, South Africa, Botswana, Eswatini

Transaction type: Debt Financing · Asset class: Private Credit · Strategy: Direct Lending · Instrument: Private Capital (Debt) · Deal amount: US$15m

Lead investor/buyer: The African Development Bank Group (AfDB) · Investors/buyers: The African Development Bank Group (AfDB)

Legal advisers: not identified in the source record.

Source: announced 5 August 2026. Original announcement: empowerafrica.com.